<DOC>
	<DOCNO>NCT00632827</DOCNO>
	<brief_summary>This study examine use denileukin diftitox ( Ontak ) patient peripheral T-cell lymphoma candidate autologous stem cell transplant .</brief_summary>
	<brief_title>Treatment PTCL With Aggressive Induction Therapy Followed Autologous SCT Using Denileukin Diftitox ( Ontak )</brief_title>
	<detailed_description>This protocol propose first increase proportion patient achieve adequate initial disease control able proceed autologous stem cell transplant ( ASCT ) first complete partial remission . It administer intensive novel induction therapy . Two cycle GND ( gemcitabine , vinorelbine , Doxil ) use follow two cycle augment dose CHOP ( Cyclophosphamide ) plus high-dose MTX . Patients restaged two cycle GND ass response GND alone second cycle augment CHOP/high-dose MTX . Those achieve remission status receive intensive consolidation HDAC/etoposide follow stem cell mobilization . A five-day course denileukin diftitox ( Ontak ) administer serve vivo purge . This follow autologous stem cell transplant . Those achieve partial remission well follow four induction course receive 2 cycle denileukin diftitox ( Ontak ) 5 day . Those achieve partial remission well regimen go consolidation/mobilization autologous stem cell transplant . Post-transplant , denileukin diftitox also use additional module therapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Histologic diagnosis follow : Peripheral Tcell lymphoma otherwise specify ( PTCLU ) , ( IPI &gt; 2 ) Angioimmunoblastic Tcell lymphoma ( IPI &gt; 2 ) Nonprimary cutaneous Alk1negative anaplastic large cell lymphoma Extranodal NK/T lymphoma ( Excluding stage I/II nasal disease ) Blastic NK cell lymphoma Enteropathy type Tcell lymphoma Subcutaneous panniculitislike Tcell lymphoma Hepatosplenic Tcell lymphoma Measurable assessable disease require . Age &gt; 18 &lt; 70 year Previously untreated 1 prior cycle chemotherapy Creatinine &lt; 2.0 mg/dL Total bilirubin &lt; 2.0 mg/dL , AST &lt; 3x upper limit normal Patients test positive HepBSAg HepC Ab eligible provide follow criterion meet : bilirubin ≤ 2 x upper limit normal ; AST ≤ 3 x upper limit normal ; liver biopsy demonstrate ≤ grade 2 fibrosis cirrhosis . Hepatitis B surface Ag ( + ) patient treat amivudine ( 3TC ) investigator 's preferred antiviral regimen throughout protocol therapy 612 month thereafter . Neutrophils &gt; 1000/uL platelet &gt; 100,000/uL Albumin &gt; 3.0 mg/dL HIVnegative No known hypersensitivity denileukin diftitox component : diptheria toxin , interleukin2 , excipients Nonpregnant , nonnursing : Treatment protocol would expose unborn child significant risk . Women men reproductive potential agree use effective mean birth control . Patients `` currently active '' second malignancy , nonmelanoma skin cancer eligible . ( This include Waldenstrom 's Macroglobulinemia , since patent experience transient increase IgM follow initiation rituximab , potential hyperviscosity syndrome require plasmapheresis ) . Patients consider `` currently active '' malignancy complete anticancer therapy , consider physician less 30 % risk relapse . PTCLU / AILT IPI 0 1 Extranodal NK/T nasal stage I/II Tlymphoblastic lymphoma Adult Tcell leukemia/lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>